Skip to main content

Articles

Prostate Cancer
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
Read More
Disparities in Oncology, Oncology
Access to Health Insurance Reduces Disparities in Cancer Care: The Case for the ACA
Phoebe Starr
Read More
Renal-Cell Carcinoma, Oncology
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
Read More
Immunotherapy, Oncology
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting
Chase Doyle
Read More
Neuroendocrine Tumors, Oncology
Combination Immune Blockade Promising in High-Grade Neuroendocrine Tumors: The DART “Basket” Clinical Trial
Phoebe Starr
Read More
Lung Cancer, Oncology
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Read More
Original Research, Practice Management
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing
Joshua A. Roth, PhD, MHA; Theo deVos, PhD; Scott D. Ramsey, MD, PhD
Read More
FDA Approvals
Eylea (Aflibercept), a VEGF Receptor Inhibitor, Receives New Indication for All Stages of Diabetic Retinopathy
Lilly Ostrovsky
Read More
FDA Approvals
Imbruvica (Ibrutinib) plus Gazyva (Obinutuzumab) First Chemotherapy-Free Combination Approved as First-Line Treatment for Patients with CLL or SLL
Lilly Ostrovsky
Read More
FDA Approvals
Mavenclad (Cladribine) First Short-Course Oral Therapy Approved for Relapsing-Remitting Multiple Sclerosis and Active Secondary Progressive Disease
Lilly Ostrovsky
Read More
Page 49 of 244
Results 481 - 490 of 2440